Cibc World Markets Corp Sells 543 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Cibc World Markets Corp reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 22.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,913 shares of the biotechnology company’s stock after selling 543 shares during the quarter. Cibc World Markets Corp’s holdings in United Therapeutics were worth $675,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of United Therapeutics during the 4th quarter worth $131,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $312.99 on Friday. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The company has a market capitalization of $14.06 billion, a price-to-earnings ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The business has a 50-day moving average of $345.10 and a 200-day moving average of $357.02.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same period last year, the company earned $4.36 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $929,678.52. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 90,255 shares of company stock valued at $32,614,521 over the last 90 days. Company insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.